Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 124c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($1.24). Revenue for the quarter came in at $35.07 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• AT&T and Dallas Cowboys extend stadium naming rights deal
• Wendy's shares slip after US franchisee files for bankruptcy